View Financial HealthDBV Technologies 配当と自社株買い配当金 基準チェック /06DBV Technologies配当金を支払った記録がありません。主要情報n/a配当利回り-19.8%バイバック利回り総株主利回り-19.8%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • May 05First quarter 2026 earnings released: US$0.11 loss per share (vs US$0.26 loss in 1Q 2025)First quarter 2026 results: US$0.11 loss per share. Net loss: US$47.6m (loss widened 76% from 1Q 2025). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.Breakeven Date Change • May 04The 6 analysts covering DBV Technologies previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 2.8% per year to 2027. The company is expected to make a profit of US$77.5m in 2028. Average annual earnings growth of 72% is required to achieve expected profit on schedule.お知らせ • May 01DBV Technologies S.A., Annual General Meeting, Jun 03, 2026DBV Technologies S.A., Annual General Meeting, Jun 03, 2026. Location: 107 avenue de la republique, chatillon FranceBoard Change • Apr 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 11+ 2 more updatesDBV Technologies S.A. to Report Q3, 2026 Results on Oct 28, 2026DBV Technologies S.A. announced that they will report Q3, 2026 results on Oct 28, 2026Reported Earnings • Mar 29Full year 2025 earnings released: US$1.05 loss per share (vs US$1.17 loss in FY 2024)Full year 2025 results: US$1.05 loss per share. Net loss: US$146.9m (loss widened 29% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.Board Change • Mar 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Mar 02Dbv Technologies Highlights Additional Data from Successful Phase 3 Vitesse Study At the Aaaai 2026 Annual MeetingDBV Technologies announced that the company shared additional positive data from the successful Phase 3 VITESSE clinical trial as an oral presentation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting, in Philadelphia, PA. VITESSE, the food allergy immunotherapy trial to date, is a Phase 3 study assessing DBV's VIASKIN®? Peanut Patch for the treatment of peanut-allergic children aged 4 to 7 years. The VITESSE study met its primary endpoint whereby VIASKIN®?Peanut demonstrated a statistically significant treatment effect (pp. The increases in eliciting dose seen are clinically meaningful and may reflect a reduced risk of an allergic reaction. Conversely, nearly four times as many children on placebo saw their eliciting dose decrease, becoming more sensitized over the twelve-month period. These results not only support the VIASKIN®? peanut Patch as a potential treatment option for peanut-allergic children, if approved, but also reinforce the importance of prioritizing a proactive treatment for this specific patient population.Board Change • Dec 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Nov 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Nov 04DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial, Effective November 3, 2025DBV Technologies announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin(R) Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA submission for 1-3 year-olds in the second half of the year. Kevin Trapp is an accomplished commercial executive with more than 30 years of experience in the biopharmaceutical industry. Before rejoining DBV, Kevin served as a consultant to the Company in his most recent role as Managing Director at Biotech Value Advisors (BVA) where he advised biotechnology boards of directors and executive leadership with product strategy, launch planning, and business evaluation. He built his career at Bristol-Myers Squibb (BMS), where he held roles of increasing responsibility across finance, sales, marketing, and general management. During his time at BMS, he managed a ~$4 billion U.S. specialty and primary care portfolio and was a key stakeholder in the planning and subsequent launches of more than 10 products and indications - including Abilify(R), Atripla(R), Reyataz(R), Orencia(R), and Daklinza(R). Mr. Trapp earned a bachelor's degree from the University of Connecticut School of Business and completed the General Management Program from the European Centre for Executive Development (CEDEP) at INSEAD.New Risk • Oct 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$98m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$98m free cash flow). Shares are highly illiquid. Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$81m net loss in 3 years).Reported Earnings • Oct 31Third quarter 2025 earnings released: US$0.24 loss per share (vs US$0.32 loss in 3Q 2024)Third quarter 2025 results: US$0.24 loss per share. Net loss: US$33.2m (loss widened 8.9% from 3Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Europe.Board Change • Oct 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Oct 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Sep 19DBV Technologies Announces Resignation of Daniel Soland as a Member of its Board of Directors, Effective September 18, 2025DBV Technologies announced the resignation of Daniel Soland, as a member of its Board of Directors, effective September 18, 2025.決済の安定と成長配当データの取得安定した配当: DBVの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: DBVの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場DBV Technologies 配当利回り対市場DBV 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (DBV)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.6%業界平均 (Biotechs)2.2%アナリスト予想 (DBV) (最長3年)0%注目すべき配当: DBVは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: DBVは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: DBVの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: DBVが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 16:47終値2026/05/29 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DBV Technologies S.A. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Tazeen AhmadBofA Global ResearchKristen KluskaCantor Fitzgerald & Co.Jonathan WollebenCitizens JMP Securities, LLC13 その他のアナリストを表示
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • May 05First quarter 2026 earnings released: US$0.11 loss per share (vs US$0.26 loss in 1Q 2025)First quarter 2026 results: US$0.11 loss per share. Net loss: US$47.6m (loss widened 76% from 1Q 2025). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
Breakeven Date Change • May 04The 6 analysts covering DBV Technologies previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 2.8% per year to 2027. The company is expected to make a profit of US$77.5m in 2028. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
お知らせ • May 01DBV Technologies S.A., Annual General Meeting, Jun 03, 2026DBV Technologies S.A., Annual General Meeting, Jun 03, 2026. Location: 107 avenue de la republique, chatillon France
Board Change • Apr 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 11+ 2 more updatesDBV Technologies S.A. to Report Q3, 2026 Results on Oct 28, 2026DBV Technologies S.A. announced that they will report Q3, 2026 results on Oct 28, 2026
Reported Earnings • Mar 29Full year 2025 earnings released: US$1.05 loss per share (vs US$1.17 loss in FY 2024)Full year 2025 results: US$1.05 loss per share. Net loss: US$146.9m (loss widened 29% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
Board Change • Mar 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Mar 02Dbv Technologies Highlights Additional Data from Successful Phase 3 Vitesse Study At the Aaaai 2026 Annual MeetingDBV Technologies announced that the company shared additional positive data from the successful Phase 3 VITESSE clinical trial as an oral presentation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting, in Philadelphia, PA. VITESSE, the food allergy immunotherapy trial to date, is a Phase 3 study assessing DBV's VIASKIN®? Peanut Patch for the treatment of peanut-allergic children aged 4 to 7 years. The VITESSE study met its primary endpoint whereby VIASKIN®?Peanut demonstrated a statistically significant treatment effect (pp. The increases in eliciting dose seen are clinically meaningful and may reflect a reduced risk of an allergic reaction. Conversely, nearly four times as many children on placebo saw their eliciting dose decrease, becoming more sensitized over the twelve-month period. These results not only support the VIASKIN®? peanut Patch as a potential treatment option for peanut-allergic children, if approved, but also reinforce the importance of prioritizing a proactive treatment for this specific patient population.
Board Change • Dec 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Nov 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Nov 04DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial, Effective November 3, 2025DBV Technologies announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin(R) Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA submission for 1-3 year-olds in the second half of the year. Kevin Trapp is an accomplished commercial executive with more than 30 years of experience in the biopharmaceutical industry. Before rejoining DBV, Kevin served as a consultant to the Company in his most recent role as Managing Director at Biotech Value Advisors (BVA) where he advised biotechnology boards of directors and executive leadership with product strategy, launch planning, and business evaluation. He built his career at Bristol-Myers Squibb (BMS), where he held roles of increasing responsibility across finance, sales, marketing, and general management. During his time at BMS, he managed a ~$4 billion U.S. specialty and primary care portfolio and was a key stakeholder in the planning and subsequent launches of more than 10 products and indications - including Abilify(R), Atripla(R), Reyataz(R), Orencia(R), and Daklinza(R). Mr. Trapp earned a bachelor's degree from the University of Connecticut School of Business and completed the General Management Program from the European Centre for Executive Development (CEDEP) at INSEAD.
New Risk • Oct 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$98m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$98m free cash flow). Shares are highly illiquid. Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$81m net loss in 3 years).
Reported Earnings • Oct 31Third quarter 2025 earnings released: US$0.24 loss per share (vs US$0.32 loss in 3Q 2024)Third quarter 2025 results: US$0.24 loss per share. Net loss: US$33.2m (loss widened 8.9% from 3Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Europe.
Board Change • Oct 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Oct 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Sep 19DBV Technologies Announces Resignation of Daniel Soland as a Member of its Board of Directors, Effective September 18, 2025DBV Technologies announced the resignation of Daniel Soland, as a member of its Board of Directors, effective September 18, 2025.